The protein syntenin-1 is expressed by a variety of cell types, and is upregulated in various malignancies, including melanoma, breast cancer and glioma. Although the mechanism by which elevated syntenin-1 expression contributes to cancer has been described, the exact pathway has not been elucidated.
To investigate the involvement of syntenin-1 in colorectal cancer (CRC), we performed immunohistochemical analysis of 139 CRC surgical specimens. We also examined syntenin-1 knockdown in CRC cell lines.
High syntenin-1 expression was associated with less differentiated histologic grade and poor prognosis, and was an independent prognostic indicator in CRC. Syntenin-1 knockdown in CRC cells reduced the presence of cancer stem cells (CSCs), oxaliplatin chemoresistance and migration. DNA microarray analysis and quantitative real-time polymerase chain reaction showed decreased prostaglandin E2 receptor 2 (PTGER2) expression in syntenin-1-knockdown cells. PTGER2 knockdown in CRC cells yielded the same phenotype as syntenin-1 knockdown. Celecoxib, which has anti-inflammatory effects by targeting cyclooxygenase-2, reduced CSCs and decreased chemoresistance, while prostaglandin E2 (PGE2) had the opposite effect.
Our findings suggested that syntenin-1 enhanced CSC expansion, oxaliplatin chemoresistance and migration capability through regulation of PTGER2 expression. Syntenin-1 may be a promising new prognostic factor and target for anti-cancer therapies.
Subscribe to Journal
Get full journal access for 1 year
only $32.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Colvin, H., Mizushima, T., Eguchi, H., Takiguchi, S., Doki, Y. & Mori, M. Gastroenterological surgery in Japan: the past, the present and the future. Ann. Gastroenterol. Surg. 1, 5–10 (2017).
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
Newcomb, P. A., Baron, J., Cotterchio, M., Gallinger, S., Grove, J., Haile, R. et al. Colon Cancer Family Registry: An international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol. Biomark. Prev. 16, 2331–2343 (2007).
Ogino, S., Kirkner, G. J., Nosho, K., Irahara, N., Kure, S., Shima, K. et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 14, 8221–8227 (2008).
Chandrasekharan, S., Foley, N. A., Jania, L., Clark, P., Audoly, L. P. & Koller, B. H. Coupling of COX-1 to mPGES1 for prostaglandin E2 biosynthesis in the murine mammary gland. J. Lipid Res. 46, 2636–2648 (2005).
Eruslanov, E., Kaliberov, S., Daurkin, I., Kaliberova, L., Buchsbaum, D., Vieweg, J. et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumour-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J. Immunol. 182, 7548–7557 (2009).
Hsu, H. H., Hu, W. S., Lin, Y. M., Kuo, W. W., Chen, L. M., Chen, W. K. et al. JNK suppression is essential for 17beta-estradiol inhibits prostaglandin E2-induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells. J. Biomed. Sci. 18, 61 (2011).
Hsu, H. H., Lin, Y. M., Shen, C. Y., Shibu, M. A., Li, S. Y., Chang, S. H. et al. Prostaglandin E2-induced COX-2 expressions via EP2 and EP4 signaling pathways in human LoVo colon cancer cells. Int. J. Mol. Sci. 25, 18 (2017).
Wang, D., Fu, L., Sun, H., Guo, L. & DuBois, R. N. Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology 149, 1884–1895 (2015).
Maust, J. D., Frankowski-McGregor, C. L., Bankhead, A. 3rd, Simeone, D. M. & Sebolt-Leopold, J. S. Cyclooxygenase-2 influences response to cotargeting of MEK and CDK4/6 in a subpopulation of pancreatic cancers. Mol. Cancer Ther. 17, 2495–2506 (2018).
Dasgupta, S., Menezes, M. E., Das, S. K., Emdad, L., Janjic, A., Bhatia, S. et al. Novel role of MDA-9/syntenin in regulating urothelial cell proliferation by modulating EGFR signaling. Clin. Cancer Res. 19, 4621–4633 (2013).
Friand, V., David, G. & Zimmermann, P. Syntenin and syndecan in the biogenesis of exosomes. Biol. Cell 107, 331–341 (2015).
Tudor, C., te Riet, J., Eich, C., Harkes, R., Smisdom, N., Bouhuijzen Wenger, J. et al. Syntenin-1 and ezrin proteins link activated leukocyte cell adhesion molecule to the actin cytoskeleton. J. Biol. Chem. 289, 13445–13460 (2014).
Cho, W., Kim, H., Lee, J. H., Hong, S. H. & Choe, J. Syntenin is exoressed in human follicular dendritic cells and involved in the activation of focal adhesion kinase. Immune Netw. 13, 199–204 (2013).
Gimferrer, I., Ibanez, A., Farnos, M., Sarrias, M. R., Fenutría, R., Roselló, S. et al. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains. J. Immunol. 175, 1406–1414 (2005).
Latysheva, N., Muratov, G., Rajesh, S., Padgett, M., Hotchin, N. A., Overduin, M. et al. Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol. Cell. Biol. 26, 7707–7718 (2006).
Chen, F., Du, Y., Zhang, Z., Chen, G., Zhang, M., Shu, H. B. et al. Syntenin negatively regulates TRAF6-mediated IL-1R/TLR4 signaling. Cell Signal. 20, 666–674 (2008).
Beekman, J. M., Verhagen, L. P., Geijsen, N. & Coffer, P. J. Regulation of myelopoiesis through syntenin-mediated modulation of IL-5 receptor output. Blood 114, 3917–3927 (2009).
Geijsen, N., Uings, I. J., Pals, C., Armstrong, J., McKinnon, M., Raaijmakers, J. A. et al. Cytokine-specific transcriptional regulation through an IL-5Ralpha interacting protein. Science 293, 1136–1138 (2001).
Sala-Valdes, M., Gordon-Alonson, M., Tejera, E., Ibáñez, A., Cabrero, J. R., Ursa, A. et al. Association of syntenin-1 with M-RIP polarizes Rac-1 activation during chemotaxis and immune interactions. J. Cell Sci. 125, 1235–1246 (2012).
Tamura, K., Ikutani, M., Yoshida, T., Tanaka-Hayashi, A., Yanagibashi, T., Inoue, R. et al. Increased production of intestinal immunoglobulins in syntenin-1-deficient mice. Immunobiology 220, 597–604 (2015).
Sobin, L. H., Gospodarowicz, M. K., Wittekind, C. (eds) TNM Classification of Malignant Tumors 7th edn (Wiley‑Blackwell, 2011).
Ohara, N., Haraguchi, N., Koseki, J., Nishizawa, Y., Kawai, K., Takahashi, H. et al. Low expression of the GOPC is a poor prognostic marker in colorectal cancer. Oncol. Lett. 14, 4483–4490 (2017).
Berg, K. C. G., Eide, P. W., Eilertsen, I. A., Johannessen, B., Bruun, J., Danielsen, S. A. et al. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Mol. Cancer 16, 116 (2017).
Sugimura, K., Fujiwara, Y., Omori, T., Motoori, M., Miyoshi, N., Akita, H. et al. Clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre- and post-lymphadenectomy from gastric cancer patients. Surg. Today 46, 654–660 (2016).
Kawai, K., Uemura, M., Munakata, K., Takahashi, H., Haraguchi, N., Nishimura, J. et al. Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis. Int. J. Oncol. 50, 525–534 (2017).
Munakata, K., Uemura, M., Takemasa, I., Ozaki, M., Konno, M., Nishimura, J. et al. SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. Int. J. Oncol. 44, 1521–1528 (2014).
Hokonohara, K., Nishida, N., Miyoshi, N., Takahashi, H., Haraguchi, N., Hata, T. et al. Involvement of MAF1 homolog, negative regulator of RNA polymerase III in colorectal cancer progression. Int. J. Oncol. 54, 1001–1009 (2019).
Boukerche, H., Aissaoui, H., Prévost, C., Hirbec, H., Das, S. K., Su, Z. Z. et al. Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappaB. Oncogene 29, 3054–3066 (2010).
Yang, Y., Hong, Q., Shi, P., Liu, Z., Luo, J. & Shao, Z. Elevated expression of syntenin in breast cancer is correlated with lymph node metastasis and poor patient survival. Breast Cancer Res. 15, R50 (2013).
Zhong, D., Ran, J. H., Tang, W. Y., Zhang, X. D., Tan, Y., Chen, G. J. et al. Mda-9/syntenin promotes human brain glioma migration through focal adhesion kinase (FAK)-JNK and FAK-AKT signaling. Asian Pac. J. Cancer Prev. 13, 2897–2901 (2012).
Qian, X. L., Li, Y. Q., Yu, B., Gu, F., Liu, F. F., Li, W. D. et al. Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. PLoS ONE 8, e60046 (2013).
Kegelman, T. P., Das, S. K., Hu, B., Bacolod, M. D., Fuller, C. E., Menezes, M. E. et al. MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol. 16, 50–61 (2014).
Cui, L., Cheng, S., Liu, X., Messadi, D., Yang, Y. & Hu, S. Syntenin-1 is a promoter and prognostic marker of head and neck squamous cell carcinoma invasion and metastasis. Oncotarget 50, 82634–82647 (2016).
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209–213 (2015).
Egea-Jimenez, A. L., Gallardo, R., Garcia-Pino, A., Ivarsson, Y., Wawrzyniak, A. M., Kashyap, R. et al. Frizzled 7 and PIP2 binding by syntenin PDZ2 domain supports Frizzled 7 trafficking and signalling. Nat. Commun. 7, 12101 (2016).
We thank the Center for Medical Research and Education, Graduate School of Medicine, Osaka University for technical assistance. We are grateful to Makoto Fujii, Ph.D. (Department of Mathematical Health Science, Osaka University Graduate School of Medicine Division of Health Sciences) for statistical evaluation.
Ethics approval and consent to participate
All experimental protocols described in this study were approved by the Institutional Ethical Review Committee (UMIN 15046-3: comprehensive agreement) and conform to the provisions of the Declaration of Helsinki. All patients provided written informed consent.
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
The authors declare no competing interests.
The present study was supported by JSPS KAKENHI Grant Numbers 18K16357 and 18K08678.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Iwamoto, K., Takahashi, H., Okuzaki, D. et al. Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-0965-9